Xtem Pharmaceuticals, Inc. was recently founded to develop novel therapeutics for Chronic Myelogenous Leukemia. Although current treatment protocols can manage this disease, in most cases this requires continuous treatment. If treatment is terminated, the disease returns due to a refractory population of stem-like cells known as leukemia initiating cells. Our technology, which was developed in the laboratory of founder, Steven Reed, Ph.D., at Scripps Research Institute, La Jolla, is designed to sensitize this resistant population of leukemia initiating cells in order to effect a complete cure that is stable in the absence of treatment. To date, we have identified small druglike molecules that look promising in cell-based assays in vitro. We are now seeking early stage investment to carry out proof of concept experiments in animal models. Ultimately, we hope to develop lead compounds that can be tested in human clinical trials.